After an siRNA or miRNA guides the RNA-induced silencing complex, sequence complementarity directs the complex toward matching messenger RNA. This recognition determines which transcript is affected. The targeted mRNA may then be degraded, or its translation may be blocked, reducing production from that gene without requiring a change to its DNA sequence.
The interaction between the guide RNA and complementary messenger RNA is central to the outcome. In some cases, targeting promotes mRNA degradation; in others, it prevents the message from being translated. These distinct outcomes both lower gene expression, but they provide different ways to interpret how RNAi has altered cellular regulation.
RNAi changes gene output at the messenger RNA level rather than modifying the underlying DNA sequence. Consequently, an observed phenotype reflects reduced expression of the targeted gene, not necessarily a permanent alteration of its genome. This distinction matters when researchers interpret results, compare experimental approaches, or design gene-regulation studies.
Researchers can reduce expression from a selected gene and then examine the resulting cellular phenotype. If the phenotype changes after the targeted transcript is silenced, the result can help link that gene to a cellular process or pathway. This functional-genomics strategy supports investigation of gene roles without directly changing the DNA sequence.
A study begins by selecting a gene whose function requires investigation, then using an siRNA or miRNA-based approach to guide RISC toward its complementary messenger RNA. Researchers evaluate the resulting reduction in gene expression and relate it to a cellular phenotype. This workflow helps test gene function and interpret pathway involvement.
RNAi can help investigate disease pathways by reducing expression of genes suspected to contribute to a biological process. It also supports drug-target validation, because silencing a candidate gene can provide functional evidence about its relevance. In addition, the approach contributes to studies of potential therapies while preserving the distinction between gene silencing and permanent genome modification.